Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Metastatic Colorectal Cancer

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44394   clinical trials with a EudraCT protocol, of which   7406   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    647 result(s) found for: Metastatic Colorectal Cancer. Displaying page 18 of 33.
    «« First « Previous 14  15  16  17  18  19  20  21  22  Next» Last»»
    EudraCT Number: 2017-002442-72 Sponsor Protocol Number: C17-01 Start Date*: 2017-10-23
    Sponsor Name:GERCOR
    Full Title: RECIST 1.1 and iRECIST evaluation for patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab. A GERCOR open-label phase II study NIPICOL C17-01
    Medical condition: Patients with deficient MMR and/or MSI Metastatic Colorectal Cancer treated with nivolumab and ipilimumab
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-002435-29 Sponsor Protocol Number: CR6086-1-04 Start Date*: 2021-09-28
    Sponsor Name:ROTTAPHARM BIOTECH S.R.L.
    Full Title: An open-label, single-arm, phase Ib/IIa trial to evaluate the safety and efficacy of the EP4 receptor antagonist CR6086 in combination with the PD-1 inhibitor balstilimab (AGEN2034), in patients wi...
    Medical condition: Pretreated mismatch-repair-proficient and microsatellite stable metastatic colorectal cancer (pMMR–MSS metastatic CRC).
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2006-004065-34 Sponsor Protocol Number: TUD-COFI06-014 Start Date*: 2006-11-24
    Sponsor Name:Technical University Dresden
    Full Title: Open labeled, multicenter phase I / II study evaluating the dose escalation/ safety of Cetuximab and Oxaliplatin/ 5-FU/FA/ Irinotecan as first-line treatment of metastatic colorectal cancer
    Medical condition: first-line treatment of metastatic colorectal cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-004200-36 Sponsor Protocol Number: BRTA-0100-014 Start Date*: 2005-12-02
    Sponsor Name:NERVIANO MEDICAL SCIENCES
    Full Title: Phase II exploratory study of brostallicin PNU-166196A as third/fourth line chemoterapy in adult patients with advanced/metastatic colorectal cancer CRC .
    Medical condition: Use for the treatment of advanced/metastatic colorectal cancer, as third/fourth line chemioterapy.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10010023 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001414-15 Sponsor Protocol Number: REVOLUTION Start Date*: 2018-07-27
    Sponsor Name:ISTITUTO NAZIONALE TUMORI - IRCCS FONDAZIONE PASCALE
    Full Title: Randomized phasE 2 study of Valproic acid in combination with bevacizumab and Oxaliplatin/fLUoropyrimidine regimens in patients with ras-mutated metastaTIc cOlorectal caNcer
    Medical condition: patients with ras-mutated metastaTIc colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10007446 Carcinoma of rectum LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2020-004636-25 Sponsor Protocol Number: ACOTAS_G098 Start Date*: 2021-06-17
    Sponsor Name:GERCOR
    Full Title: A phase II study to evaluate the rate of cardiovascular events during trifluridine/tipiracil +/-oxaliplatin treatment in colorectal/oesogastric adenocarcinoma patients that have experienced a pas...
    Medical condition: colorectal or oesogastric adenocarcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052360 Colorectal adenocarcinoma PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10017758 Gastric cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002797-56 Sponsor Protocol Number: C04-2 Start Date*: 2007-08-28
    Sponsor Name:Gercor
    Full Title: Phase III study of an optimized chemotherapy + Avastin strategy +/- Tarceva in metastatic colorectal cancer.
    Medical condition: Metastatic Colorectal Cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-002849-11 Sponsor Protocol Number: FIRE-5 Start Date*: 2019-06-17
    Sponsor Name:Klinikum der Universität München, Ludwig-Maximilians-Universität München, represented by the managing medical director
    Full Title: Optimal anti-EGFR Treatment of mCRC Patients with Low-Frequency RAS Mutation
    Medical condition: RAS-mutant metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-005758-64 Sponsor Protocol Number: INCA06-FT/STIC-AVASTIN Start Date*: 2007-01-16
    Sponsor Name:CHRU TOURS
    Full Title: Evaluation médico-économique de l'échographie de contraste pour l'appréciation précoce de l'effet du bevacizumab sur les métastases hépatiques de cancer colorectal
    Medical condition: cancer colorectal avancé avec au moins une métastase hépatique
    Disease: Version SOC Term Classification Code Term Level
    8.1 10052358 Colorectal cancer metastatic LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005003-32 Sponsor Protocol Number: ORCHESTRA Start Date*: 2012-06-14
    Sponsor Name:VU University Medical Center, Department of Medical Oncology
    Full Title: A randomized multicenter clinical trial for patients with multi-organ, colorectal cancer metastases comparing the combination of chemotherapy and maximal tumor debulking versus chemotherapy alone.
    Medical condition: multi-organ metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2014-001017-61 Sponsor Protocol Number: MO29112 Start Date*: 2014-11-08
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A MULTI-CENTRE RANDOMISED CLINICAL TRIAL OF BIOMARKER-DRIVEN MAINTENANCE TREATMENT FOR FIRST-LINE METASTATIC COLORECTAL CANCER (MODUL)
    Medical condition: METASTATIC COLORECTAL CANCER
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) GB (GB - no longer in EU/EEA) DE (Completed) PT (Completed) DK (Completed) SK (Prematurely Ended) NL (Completed) FR (Completed) SE (Completed) BE (Completed) GR (Completed) ES (Temporarily Halted) SI (Completed) CY (Completed)
    Trial results: View results
    EudraCT Number: 2022-001459-17 Sponsor Protocol Number: NuTide:323 Start Date*: 2023-03-27
    Sponsor Name:NuCana plc
    Full Title: A randomised, open-label, Phase II, dose/schedule optimisation study of NUC-3373/leucovorin/irinotecan plus bevacizumab (NUFIRI-bev) versus 5-FU/leucovorin/irinotecan plus bevacizumab (FOLFIRI-bev)...
    Medical condition: Relapsed, unresectable, histologically or cytologically confirmed metastatic adenocarcinoma of colon or rectum with radiologically measurable disease.
    Disease: Version SOC Term Classification Code Term Level
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052358 Colorectal cancer metastatic PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) DE (Prematurely Ended) IT (Prematurely Ended) FR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-000490-79 Sponsor Protocol Number: AB12006 Start Date*: 2015-09-18
    Sponsor Name:AB Science
    Full Title: A prospective, multicenter, randomized, double blind, placebo-controlled, 2-parallel groups, phase 3 study to compare the efficacy and safety of masitinib in combination with FOLFIRI (irinotecan, 5...
    Medical condition: Metastatic colorectal cancer after 1 previous line of treatment
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended) ES (Completed) CZ (Completed) SK (Prematurely Ended) HU (Completed) GB (Prematurely Ended) FR (Completed) CY (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2008-003258-14 Sponsor Protocol Number: 20070307 Start Date*: 2008-11-14
    Sponsor Name:Amgen Inc
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo Controlled Study of AMG 386 in Combination with FOLFIRI in Subjects with Previously Treated Metastatic Colorectal Carcinoma
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2019-002071-34 Sponsor Protocol Number: ALLOCATE Start Date*: 2019-10-31
    Sponsor Name:Vejle Hospital
    Full Title: Allocation of patients with pre-treated solid tumors to anti-cancer therapy based on gene expression drug response prediction - a phase II basket trial
    Medical condition: Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10072737 Advanced breast cancer LLT
    20.0 100000004864 10033130 Ovarian cancer NOS LLT
    20.1 100000004864 10080083 Advanced lung cancer LLT
    20.0 100000004864 10052362 Metastatic colorectal cancer LLT
    20.0 100000004864 10033605 Pancreatic cancer metastatic LLT
    20.0 100000004864 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-003737-25 Sponsor Protocol Number: STX0206-SIRFLOXstudy Start Date*: 2008-11-26
    Sponsor Name:Sirtex Technology Pty Ltd
    Full Title: Randomised comparative study of folfox6m plus SIR-Spheres microspheres versus folfox6m alone as first line treatment in patients with non-resectable liver metastases from primary colorectal carcinoma
    Medical condition: Non-resectable liver metastasis from primary colorectal carcinoma
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005547-27 Sponsor Protocol Number: GO28074 Start Date*: 2012-10-24
    Sponsor Name:Genentech, Inc.
    Full Title: A PHASE II, MULTICENTER, OPEN-LABEL, RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF FOLFIRI + MEHD7945A VERSUS FOLFIRI + CETUXIMAB IN SECOND LINE IN PATIENTS WITH KRAS WILD-TYPE METASTATIC ...
    Medical condition: Colorectal cancer that does not carry mutation in the KRAS gene
    Disease: Version SOC Term Classification Code Term Level
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10001167 Adenocarcinoma of colon PT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10010029 Colorectal cancer NOS LLT
    17.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10038019 Rectal adenocarcinoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) BE (Completed) ES (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-023695-91 Sponsor Protocol Number: SoMore version 2.0 Start Date*: 2010-12-29
    Sponsor Name:Institut Jules Bordet
    Full Title: Sorafenib plus capecitabine activity assesment in patients with advanced pre-treated colorectal cancer
    Medical condition: Histologically confirmed colorectal cancer that is metastatic or unresectable and for which standard curative or palliative measures do not exist or are no longer effective. Age >18 years. Life exp...
    Disease: Version SOC Term Classification Code Term Level
    14.0 10022891 - Investigations 10034750 PET scan abnormal LLT
    14.0 10042613 - Surgical and medical procedures 10008452 Chemotherapy multiple agents systemic PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2015-004849-11 Sponsor Protocol Number: AIO-KRK-0116 Start Date*: 2016-09-29
    Sponsor Name:University Clinic od Munich-Großhadern (represented by the medical management)
    Full Title: Randomised study to investigate FOLFOXIRI plus cetuximab or FOLFOXIRI plus bevacizumab as first-line treatment of BRAF-mutated metastatic colorectal cancer (FIRE-4.5)
    Medical condition: Histologically confirmed, UICC stage IV adenocarcinoma of the colon or rectum with metastases (metastatic colorectal cancer, mCRC), primarily non-resectable or surgery refused by the patient; RAS ...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10052362 Metastatic colorectal cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-001210-15 Sponsor Protocol Number: MOU-2017-02 Start Date*: 2018-11-19
    Sponsor Name:Masarykův onkologický ústav
    Full Title: Rational Anti-EGFR therapy Selection for the first-line treatment of patients with metastatic KRAS/NRAS wild type colorectal cancer based on the use of molecular predictor miR-31-5p (RASmiR)
    Medical condition: inoperable, untreated, wild type RAS (wt KRAS/wtNRAS), metastatic colorectal cancer (mCRC)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 14  15  16  17  18  19  20  21  22  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 16 23:32:37 CEST 2026 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA